1. Seidman, A., Hudis, C., Pierri, M. K. et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. doi: 10.1200/JCO.20.5.1215 .
2. Ewer, M. S., Gibbs, H. R., Swafford, J., & Benjamin, R. S. (1999). Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact? Seminars in Oncology, 26, 96–101.
3. Keefe, D. L. (2002). Trastuzumab-associated cardiotoxicity. Cancer, 95, 1592–1600. doi: 10.1002/cncr.10854 .
4. Lange, S. A., Ebner, B., Astrid, W., et al. (2013). Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy. Clinical Research in Cardiology, 100(1). http://medcontent.metapress.com/index/A65RM03P4874243N.pdf . Accessed December 4, 2013.
5. Biswas, M., Sudhakar, S., Nanda, N. C., et al. (2013). Two- and three-dimensional speckle tracking echocardiography: Clinical applications and future directions. Echocardiography., 30(1), 88–105. doi: 10.1111/echo.12079 .